Abstract
NAP is a short octapeptide sequence (single letter code, NAPVSIPQ) that protects neurons against a wide variety of insults. The NAP sequence was identified by peptide structure/function scanning of activity-dependent neuroprotective protein (ADNP), a gene product essential for brain formation. To further evaluate the in vivo efficacy of NAP neuroprotection we used a mouse model of head trauma; a condition that presents a risk factor for the development of Alzheimers disease in injured patients. In the mouse model, NAP treatment (prophylactic or curative) indicated improvement in longitudinal clinical, biochemical and anatomical outcomes. Furthermore, closed head injury was associated with a delayed increase in the expression of the immune cell surface glycoprotein Mac-1 (CD11B antigen) at the injury site that was decreased in NAP-treated mice. Additional experiments with Mac-1-deficient mice suggested partial protection against death related to severe head injury. NAP protection in Mac-1-deficient mice against adverse clinical outcome was concomitant with the time period when increases in Mac-1 transcripts were observed in the Mac-1 expressing mice (∼four weeks after the injury). The expression of ADNP (the NAP parent protein) was also increased at the injured brain site four weeks after the traumatic event, only in Mac-1 expressing mice. Here, using immunocytochemistry, we localized the increase in ADNP to microglia and astrocyte-like cells. The increase in ADNP in injured brains is now suggested to be a part of an endogenous compensatory mechanism and NAP treatment provides an additional protection. Toxicology studies suggest NAP as safe for further clinical development.
Keywords: neuropeptide, adnp gene, neuroprotection, astrocytes, cdna, polymorphonuclear neutrophils (pmn), water maze test, mac-1, –, deficient mice, expression
Current Alzheimer Research
Title: The Expression of Activity-Dependent Neuroprotective Protein (ADNP) is Regulated by Brain Damage and Treatment of Mice with the ADNP Derived Peptide, NAP, Reduces the Severity of Traumatic Head Injury
Volume: 2 Issue: 2
Author(s): Illana Gozes, Roy Zaltzman, Janet Hauser, Douglas E. Brenneman, Esther Shohami and Joanna M. Hill
Affiliation:
Keywords: neuropeptide, adnp gene, neuroprotection, astrocytes, cdna, polymorphonuclear neutrophils (pmn), water maze test, mac-1, –, deficient mice, expression
Abstract: NAP is a short octapeptide sequence (single letter code, NAPVSIPQ) that protects neurons against a wide variety of insults. The NAP sequence was identified by peptide structure/function scanning of activity-dependent neuroprotective protein (ADNP), a gene product essential for brain formation. To further evaluate the in vivo efficacy of NAP neuroprotection we used a mouse model of head trauma; a condition that presents a risk factor for the development of Alzheimers disease in injured patients. In the mouse model, NAP treatment (prophylactic or curative) indicated improvement in longitudinal clinical, biochemical and anatomical outcomes. Furthermore, closed head injury was associated with a delayed increase in the expression of the immune cell surface glycoprotein Mac-1 (CD11B antigen) at the injury site that was decreased in NAP-treated mice. Additional experiments with Mac-1-deficient mice suggested partial protection against death related to severe head injury. NAP protection in Mac-1-deficient mice against adverse clinical outcome was concomitant with the time period when increases in Mac-1 transcripts were observed in the Mac-1 expressing mice (∼four weeks after the injury). The expression of ADNP (the NAP parent protein) was also increased at the injured brain site four weeks after the traumatic event, only in Mac-1 expressing mice. Here, using immunocytochemistry, we localized the increase in ADNP to microglia and astrocyte-like cells. The increase in ADNP in injured brains is now suggested to be a part of an endogenous compensatory mechanism and NAP treatment provides an additional protection. Toxicology studies suggest NAP as safe for further clinical development.
Export Options
About this article
Cite this article as:
Gozes Illana, Zaltzman Roy, Hauser Janet, Brenneman E. Douglas, Shohami Esther and Hill M. Joanna, The Expression of Activity-Dependent Neuroprotective Protein (ADNP) is Regulated by Brain Damage and Treatment of Mice with the ADNP Derived Peptide, NAP, Reduces the Severity of Traumatic Head Injury, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585873
DOI https://dx.doi.org/10.2174/1567205053585873 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells as Mediators of Neural Differentiation
Current Stem Cell Research & Therapy Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Current Pharmaceutical Design A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Investigation of Image Processing Techniques in MRI Based Medical Image Analysis Methods and Validation Metrics for Brain Tumor
Current Medical Imaging Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Ferrous Ion Chelating Modification and Treatment of Iron-Deficiency Anemia of Exopolysaccharide from Lachnum sp.
Current Chemical Biology Anthrax Fusion Protein Therapy of Cancer
Current Protein & Peptide Science Ginsenoside RB1 Reduces Neurologic Damage, is Anti-Apoptotic, and Down-Regulates p53 and BAX in Subarachnoid Hemorrhage
Current Neurovascular Research Cerebral Hemorrhage Produced by Thrombolytic and Anti-Thrombotic Agents: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease: Is Inflammatory Signaling a Key Player?
Current Alzheimer Research Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design Recent Evidence of the Regulatory Role of PPARs in Neural Stem Cells and Their Underlying Mechanisms for Neuroprotective Effects
Current Stem Cell Research & Therapy Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry SUBJECT INDEX
Adolescent Psychiatry